Home >Circulating Tumor Cell Test/ Cancer Stem Cell treatment
Over the past 10 years, the RGCC test has become one of the most accurate and complete diagnoses performed by liquid biopsy.
RGCC uses only a single blood sample for all cancers (solid tumors, hematologic, sarcomas, etc.) except for primary tumors of the brain and central nervous system (glioblastomas, astrocytomas, meningiomas, etc.). The test requires an invasive tissue biopsy.
At this stage, it is noteworthy that RGCC analysis focuses on stopping circulating tumor cells (CTCs) and cancer stem cells (CSCs) from causing metastatic tumors, which account for at least 90% of all cancer-related deaths.
CTCs and CSCs have all the information and ability to form microclones, which often become effective micrometastases. This is the reason for cancer recurrence. For this reason, the RGCC has chosen blood samples as the most appropriate medium of analysis because it includes CTCs with the most relevant information for calculating the risk of potential metastasis and/or de novo occurrence for months to years.
(CTCs) are found in patients with various forms of metastatic carcinomas and from solid tumors dispersed in peripheral blood. It is generally explained that these cells are separated from the primary or secondary tumors of advanced cancer patients prior to detection in the bloodstream. The number of CTCs is considered much smaller with an estimated number of one in 100 million for one in a billion blood cells.
Scientists have discovered a test that could revolutionize the way doctors evaluate and treat cancer patients. The technique involves the detection of circulating tumor cells in the blood and genetic testing. Understanding tumor cells is extremely important because it is the spread of cancer to other parts of the body – not the primary cancer – that is often the cause of death in cancer patients.
Despite current advances in cancer treatment, tumor recurrence and metastasis remain a clinical challenge. A potential new approach to address this problem is to target a subset of the tumor cell population, known as CSC or cancer stem cells (stem cells).
Cancer stem cells are highly tumorigenic, have a high metastatic potential, and are resistant to conventional cancer therapies.
In the clonal evolutionary model, all cells within a malignant tumor have similar tumorigenic activity. In contrast, only a subset of tumor cells, the CSCs, have the ability to initiate tumors. This may help explain why early tumor shrinkage is often not a good predictor of overall survival. Although conventional therapies kill most non-principal cancer cells, leading to tumor shrinkage, CSCs may still survive and later restore the tumor, leading to recurrence.
We provide the best medical care, health care products for our patients. And we also offer a variety of leading cancer treatment options to help you significantly improve the effectiveness of your fight against cancer. Let you have a healthy and good life.
Copyright © 2022 Fortune One. Developed by Channel Soft PLT
English 
Chinese